Skip to main content

Table 1 Baseline patients’ characteristics

From: Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)

Characteristic Total number of patients (N = 36)
Age, years
 Median 66
 Range 25–83
Sex, n (%)
 Female 32 (88.9)
 Male 4 (11.1)
Time since del5q diagnosis (months)
 Median 10
 Range 1–83
IPSS risk score, n (%)
 0 14 (38.9)
 0.5 22 (61.1)
Number of previous treatment lines
 0 18
 1 6
 2 8
 3 4
Transfusion dependency (months)
 Median 10
 Range 2–47
RBC transfusion units/8 weeks
 Median 2
 Range 1–10
Absolute neutrophil count (ANC), x 109/l
 Median 1.6
 Range 0.4–5.2
Baseline hemoglobin level, g/dl
 Median 7.4
 Range 5.2–8
Baseline platelet count, x 109/l
 Median 259
 Range 102–742
Myelogram
 High cellularity 30
 Low cellularity 6
Bone marrow dysplasia
 1 line 8
 2 lines 16
 3 lines 12
Lactate dehydrogenase (LDH) level, n (%)
 Normal 13 (36.1)
 Increased 23 (63.9)
Ferritin level
 Elevated 26
 Missing 10
\